FDA Extends Review of Pfizer’s Inhaled Insulin
From Bloomberg News
Pfizer Inc. said U.S. regulators extended its review period for Exubera, an inhaled insulin treatment that could serve as an alternative to needles for 4 million American diabetics.
The Food and Drug Administration needs as long as three months to look at additional data provided by the companies, New York-based Pfizer said.
Pfizer developed Exubera, the first treatment of its type, with Nektar Therapeutics of San Carlos, Calif., and Sanofi-Aventis of Paris.
